Trial Profile
Impact of the Combination of Durvalumab (MEDI4736) Plus Olaparib (AZD2281) Administered Prior to Surgery in the Molecular Profile of Resectable Urothelial Bladder Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Mar 2022
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Olaparib (Primary)
- Indications Bladder cancer; Carcinoma; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms NEODURVARIB
- 19 Feb 2022 Results evaluating the basal molecular profiles and their evolution under treatment with this combination, presented at the 2022 Genitourinary Cancers Symposium
- 21 Sep 2020 Results assessing efficacy and safety of neoadjuvant combination of durvalumab plus olaparib in resectable urothelial bladder cancer, presented at the 45th European Society for Medical Oncology Congress
- 03 Apr 2020 Status changed from recruiting to completed.